The purpose of the research study is to determine the effects of two different kinds of speech treatment on certain behaviors in individuals with parkinson''''s disease. Theses behaviors include speech, voice, related communication behaviors, swallowing and body movement.

Condition	Intervention	Phase
Parkinson''''s Disease Dysphagia Dysarthria	Behavior: Voice/Respiration Treatment  Behavior: Speech/Articulation Treatment	Phase III

Ages Eligible for Study:  45 Years   -   85 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria: - Idiopathic Parkinson''''s Disease (IPD) -none or mild dementia -none, mild or moderate depression -mild, moderate or severe speech, voice, and swallowing disorder

Exclusion Criteria: -severe depression -moderate or severe dementia -symptoms of another neurological condition other than or in addition to IPD or drug abuse -head or neck cancer -significant history of gastrointestinal disease or surgery -speech or voice disorders unrelated to IPD -neurological or laryngeal surgical treatment (related or unrelated to IPD) -laryngeal pathology -full-course Lee Silverman Voice Treatment(LSVT®) -smoked in last four years, -absence of speech, voice or swallowing disorder -severe temporomandibular joint disorder -pregnancy (or the possibility of pregnancy). -Hearing loss unexpected for his/her chronological age

Please refer to this study by ClinicalTrials.gov identifier  NCT00123084

Jill A Petska, MS, CCC-SLP      303-893-6025    jpetska@dcpa.org

Colorado
      National Center for Voice and Speech, division of the Denver Center for the Performing Arts, Denver,  Colorado,  80204,  United States; Recruiting

Study chairs or principal investigators

Lorraine Ramig, PhD, CCC-SLP,  Principal Investigator,  Professor, University of Colorado-Boulder; Senior Scientist, National Center for Voice and Speech-Denver; Adjunct Professor, Columbia University-NYC   

Study ID Numbers:  R01 DC01150
Record last reviewed:  July 2005
Last Updated:  July 25, 2005
Record first received:  July 21, 2005
ClinicalTrials.gov Identifier:  NCT00123084
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-07-26